Insufficient scRNA-seq data for expression of IGHV3-16 at single-cell level.
Insufficient scRNA-seq data for expression of IGHV3-16 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
spleen | 89% | 12.37 | 214 / 241 | 0% | 0 | 0 / 0 |
intestine | 43% | 4.74 | 411 / 966 | 5% | 0.18 | 26 / 527 |
stomach | 37% | 2.62 | 133 / 359 | 6% | 0.10 | 18 / 286 |
lung | 33% | 1.80 | 192 / 578 | 10% | 0.40 | 116 / 1155 |
breast | 21% | 1.26 | 97 / 459 | 2% | 0.04 | 20 / 1118 |
peripheral blood | 22% | 1.36 | 203 / 929 | 0% | 0 | 0 / 0 |
thymus | 12% | 0.97 | 81 / 653 | 5% | 0.10 | 33 / 605 |
bladder | 14% | 0.52 | 3 / 21 | 3% | 0.06 | 14 / 504 |
kidney | 10% | 0.49 | 9 / 89 | 1% | 0.02 | 10 / 901 |
esophagus | 6% | 0.38 | 89 / 1445 | 3% | 0.09 | 5 / 183 |
ovary | 6% | 0.14 | 11 / 180 | 1% | 0.01 | 3 / 430 |
uterus | 4% | 0.12 | 7 / 170 | 2% | 0.05 | 10 / 459 |
liver | 5% | 0.26 | 12 / 226 | 0% | 0.03 | 2 / 406 |
prostate | 4% | 0.33 | 10 / 245 | 1% | 0.03 | 4 / 502 |
tonsil | 0% | 0 | 0 / 0 | 4% | 0.27 | 2 / 45 |
blood vessel | 4% | 0.21 | 59 / 1335 | 0% | 0 | 0 / 0 |
adipose | 4% | 0.16 | 48 / 1204 | 0% | 0 | 0 / 0 |
adrenal gland | 3% | 0.10 | 7 / 258 | 1% | 0.01 | 2 / 230 |
pancreas | 2% | 0.07 | 8 / 328 | 1% | 0.02 | 2 / 178 |
skin | 1% | 0.03 | 20 / 1809 | 2% | 0.06 | 11 / 472 |
heart | 1% | 0.03 | 10 / 861 | 0% | 0 | 0 / 0 |
muscle | 1% | 0.04 | 7 / 803 | 0% | 0 | 0 / 0 |
brain | 1% | 0.01 | 14 / 2642 | 0% | 0.00 | 2 / 705 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016064 | Biological process | immunoglobulin mediated immune response |
GO_0019814 | Cellular component | immunoglobulin complex |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0003823 | Molecular function | antigen binding |
Gene name | IGHV3-16 |
Protein name | Probable non-functional immunoglobulin heavy variable 3-16 |
Synonyms | |
Description | FUNCTION: Probable non-functional open reading frame (ORF) of V region of the variable domain of immunoglobulin heavy chains . Non-functional ORF generally cannot participate in the synthesis of a productive immunoglobulin chain due to altered V-(D)-J or switch recombination and/or splicing site (at mRNA level) and/or conserved amino acid change (protein level) . Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens . The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen . . |
Accessions | ENST00000631755.1 ENST00000390604.2 A0A0C4DH30 |